| pubmed-article:7802860 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7802860 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:7802860 | lifeskim:mentions | umls-concept:C0330390 | lld:lifeskim |
| pubmed-article:7802860 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:7802860 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:7802860 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:7802860 | lifeskim:mentions | umls-concept:C1710236 | lld:lifeskim |
| pubmed-article:7802860 | lifeskim:mentions | umls-concept:C0560013 | lld:lifeskim |
| pubmed-article:7802860 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:7802860 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:7802860 | pubmed:dateCreated | 1994-3-1 | lld:pubmed |
| pubmed-article:7802860 | pubmed:abstractText | Cells from patients with acute myeloid leukaemia (AML) contain an abnormally high UDP-GlcNAc: Gal beta 1-3GalNAc-R (GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase (core 2 beta 6-Gn-T) activity. Upon UV irradiation at 350 nm, the substrate Gal beta 1-3GalNAc alpha-p-nitrophenyl acted as an effective inhibitor for this enzyme but not for several other transferases. Preincubation with Gal beta 1-3GalNAc alpha-benzyl but not GalNAc alpha-benzyl protected core 2 beta 6-Gn-T from inhibition indicating that the inhibitor is specific for the substrate binding site of core 2 beta 6-Gn-T. A number of other nitrophenyl-sugar derivatives similarly acted as inhibitors for core 2 beta 6-Gn-T. GalNAc alpha-pnp at higher concentrations also inactivated UDP-Gal: GalNAc-R beta 3-galactosyltransferase from rat liver and AML cells and inhibition could be reduced by substrate protection. These results suggest that pnp-sugar derivatives may prove useful as specific inhibitors of glycosyltransferases and as affinity labels. | lld:pubmed |
| pubmed-article:7802860 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7802860 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7802860 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7802860 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7802860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7802860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7802860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7802860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7802860 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7802860 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7802860 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:7802860 | pubmed:issn | 0006-291X | lld:pubmed |
| pubmed-article:7802860 | pubmed:author | pubmed-author:BakerM AMA | lld:pubmed |
| pubmed-article:7802860 | pubmed:author | pubmed-author:MattaK LKL | lld:pubmed |
| pubmed-article:7802860 | pubmed:author | pubmed-author:BrockhausenII | lld:pubmed |
| pubmed-article:7802860 | pubmed:author | pubmed-author:ReckFF | lld:pubmed |
| pubmed-article:7802860 | pubmed:author | pubmed-author:KuhnsWW | lld:pubmed |
| pubmed-article:7802860 | pubmed:author | pubmed-author:TokiDD | lld:pubmed |
| pubmed-article:7802860 | pubmed:author | pubmed-author:GranovskyM... | lld:pubmed |
| pubmed-article:7802860 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7802860 | pubmed:day | 28 | lld:pubmed |
| pubmed-article:7802860 | pubmed:volume | 198 | lld:pubmed |
| pubmed-article:7802860 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7802860 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7802860 | pubmed:pagination | 417-23 | lld:pubmed |
| pubmed-article:7802860 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7802860 | pubmed:meshHeading | pubmed-meshheading:7802860-... | lld:pubmed |
| pubmed-article:7802860 | pubmed:meshHeading | pubmed-meshheading:7802860-... | lld:pubmed |
| pubmed-article:7802860 | pubmed:meshHeading | pubmed-meshheading:7802860-... | lld:pubmed |
| pubmed-article:7802860 | pubmed:meshHeading | pubmed-meshheading:7802860-... | lld:pubmed |
| pubmed-article:7802860 | pubmed:meshHeading | pubmed-meshheading:7802860-... | lld:pubmed |
| pubmed-article:7802860 | pubmed:meshHeading | pubmed-meshheading:7802860-... | lld:pubmed |
| pubmed-article:7802860 | pubmed:meshHeading | pubmed-meshheading:7802860-... | lld:pubmed |
| pubmed-article:7802860 | pubmed:meshHeading | pubmed-meshheading:7802860-... | lld:pubmed |
| pubmed-article:7802860 | pubmed:meshHeading | pubmed-meshheading:7802860-... | lld:pubmed |
| pubmed-article:7802860 | pubmed:meshHeading | pubmed-meshheading:7802860-... | lld:pubmed |
| pubmed-article:7802860 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7802860 | pubmed:articleTitle | Inhibition of UDP-GlcNAc:Gal beta 1-3GalNAc-R (GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase from acute myeloid leukaemia cells by photoreactive nitrophenyl substrate derivatives. | lld:pubmed |
| pubmed-article:7802860 | pubmed:affiliation | Department of Biochemistry, Hospital for Sick Children, Toronto, Ontario, Canada. | lld:pubmed |
| pubmed-article:7802860 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7802860 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7802860 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
